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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground: Urinary tract infection (UTI) is one of the most prevalent admission diagnoses in
hospital-based clinical practice. Despite its frequency, few data are available regarding its de-
mographics and economic implications.
Purpose: To describe the demography, epidemiology, and burden of care of patients admitted
to hospital with UTI and compare these characteristics depending on admission status.
Methods: A retrospective cohort study using an administrative database of patients admitted
to Hartford Hospital (September 2011eAugust 2012) with UTI. Patient demographics, hospital
characteristics, and total costs of care were examined.
Results: A total of 2345 unique patients were included. The mean age of the patients was 78
years and 71% were female. Median length of stay and total cost were 5 days and $8326 (inter-
quartile range $5388e$14,179), respectively. A total of 359 patients (16.4%) were readmitted
within 30 days, of which 111 patients (5.1%) had UTI on readmission. Only 16.3% of readmitted
patients were infected with the same causative pathogen. A significant increase in the inci-
dence of Enterococcus faecalis (1.2% vs. 9.3%; pZ 0.046) occurred upon readmission, whereas
occurrence of Enterobacteriaceae infection decreased in the readmission group (50.0% vs.
25.6%; p Z 0.006), including a lower proportion of Escherichia coli (32.5% vs. 11.6%;
p < 0.001). A higher proportion of readmission pathogens were nonsusceptible, including sig-
nificant changes to cefazolin (24.4% vs. 63.6%; p Z 0.004) and cefepime (8.7% vs. 27.6;
p Z 0.05).at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy held in Denver, CO,
nti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102,
health.org (D.P. Nicolau).
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518 S.H. MacVane et al.Conclusion: UTI is highly prevalent and is associated with significant utilization of health-care
resources among hospitalized patients. These findings, coupled with considerable rates of 30-
day readmission, stress the importance of proper diagnosis and treatment.
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reserved.Introduction
Urinary tract infection (UTI) is one of the most common
diagnoses in patients admitted to hospitals. UTI accounts
for nearly 1 million emergency department visits and over
100,000 hospital admissions annually in the United States.1
In addition, UTI is estimated to cost $3.5 billion to the
health-care system, a significant financial burden.2 Despite
the sizeable prevalence, data on the demography, uro-
pathogen distribution, and burden of care of patients hos-
pitalized with UTI are scarce. Because of the array of
potential causative organisms, hospitalized patients often
require use of broad-spectrum antibiotics empirically,
generating higher rates of antimicrobial resistance.3
Furthermore, due to UTI frequency and the aging popula-
tion, readmissions to hospital are plentiful. Given the
evolving health-care reimbursement process linking quality
of care to payment in many disease states, it appears
paramount to gain an appreciation for the consequences of
this resource-demanding infection.
Hospital readmissions in the UTI population may be
related to a number of factors, including failure of anti-
microbial therapy, reoccurrence of infection, or unplanned
or unrelated issues, among others. Because of this
complexity, we sought to identify trends and relationships
between demographics, epidemiology, and treatment,
across admissions of patients readmitted to hospital with
UTI. Through the identification of areas of potential
improvement and future study in the management of pa-
tients with UTI, quality of care and consistency can ulti-
mately be improved.Methods
Study patients and design
We retrospectively studied the demographic, microbio-
logic, and economic attributes of patients admitted to
Hartford Hospital (CT, USA) with a diagnosis of UTI on
admission (48 hours). The study included adult patients
(aged >18 years) identified from an administrative data-
base using International Classification of Diseases 9th Edi-
tion Clinical Modification code (ICD-9-CM) 599.0 in the
primary or secondary diagnosis field from September 1,
2011 to August 30, 2012. Patients were included in the
primary analysis only on their first admission (index
admission) during the study period, and any future admis-
sions were excluded from the primary analysis. Patients
who died while hospitalized or those who were placed on
inpatient hospice care were excluded from the readmission
analysis as they were inevitably not at risk for readmission.The study was approved by the Institutional Review
Board of Hartford Hospital. An informed consent waiver was
granted as all data were currently in existence and no
patient-specific interventions were conducted for the
retrospective study. The collection of data was in compli-
ance with the Health Insurance Portability and Account-
ability Act of 1996.
Data collection
Data collected from the administrative database included
patient demographics, and hospital and discharge charac-
teristics. Cost of overall hospitalization and payor mix were
retrieved for the economic analysis.
In addition to the administrative data, the medical re-
cords (index and readmission visits) of all qualified patients
with a UTI-related readmission within 30 days of discharge
were assessed for the following key information: comorbid
conditions, recent hospitalization, recent antibiotic ther-
apy, causative urinary pathogen, and antibiotic therapy.
For purposes of evaluating the potential development of
resistance across admissions, we ascertained the causative
organism and susceptibility of readmitted patient’s UTI on
each hospital visit.
End points and definitions
UTI was defined by the presence of either primary or sec-
ondary ICD-9-CM code 599.0. The 599.0 code was purposely
chosen to be broad, to identify all patients with UTI
(regardless of site specificity), because the standards used
by coders and billers when deciding to apply a UTI diagnosis
are inexact and general in nature. Likewise, in clinical
settings, providers may diagnose and treat patients in the
absence of classic signs and symptoms of UTI or without
knowledge of the site and type of infection.4 This allowed
us to capture those patients billed for UTI to better un-
derstand the extent of the demographic and economic
implications of the diagnosis on the health-care system.
Hospital readmission was defined as a pair of consecu-
tive hospital admissions to Hartford Hospital, where the
time between discharge from the first hospitalization and
admission for the second hospitalization was less than or
equal to 30 days. No distinction was made in terms of type
of readmission, that is, planned versus unplanned.
An initial antibiotic treatment was a course of therapy
initiated empirically (before availability of in vitro sus-
ceptibility reports). We considered an empiric antibiotic to
be appropriate if it ultimately possessed in vitro activity
against the isolated pathogen. At our institution, the
preferred empiric antimicrobial agents for community-
acquired and health-care-associated UTI are ceftriaxone
UTI demography and burden of care 519and cefepime (vancomycin), respectively. Time to
appropriate antibiotics was defined as the elapsed time
(hours) between the index culture collection and the initial
dose of appropriate antibiotic therapy.
Hospital costs were calculated as the direct plus indirect
hospitalization costs for each patient. Billing and financial
information were retrieved from the hospital’s accounting
system. All economic values were reported in U.S. dollars.
Statistical analysis
Continuous variables were compared using Student t test,
paired t test or theWilcoxon signed rank test, as appropriate.
Categorical variables were compared using the Chi-square
test, Fisher’s exact test, or McNemar’s test, as appropriate.
A p value 0.05 was considered statistically significant. All
statistical analyses were performed using SigmaPlot, version
12 (Systat Software, Inc., San Jose, CA, USA).
Results
Administrative database
Patient population
A total of 2345 patients were admitted to Hartford Hospital
with UTI. Among these patients, 493 (21%) patients had a
primary discharge diagnosis and 1852 (79%) had a secondary
diagnosis. A total of 2193 (93.5%) patients were evaluableFigure 1. Inclusion and exclusion criteria flowchart of patients in
with no urinary tract infection (UTI) on readmission, five with coloni
admission, four with psychiatry admission, two with extended non-Ufor readmission. A flowchart of the inclusion and exclusion
criteria for each study cohort is depicted in Fig. 1. Patients
with a primary diagnosis of UTI were older than patients
with a secondary diagnosis. Other demographics were
comparable between diagnoses type.
A total of 359 (16.4%) patients were readmitted to hos-
pital within 30 days of discharge. There was no difference
in 30-day readmission rates between patients with a pri-
mary or secondary diagnosis (14.4% vs. 15.6%; p Z 0.557).
Male patients were more likely to be readmitted within 30
days than females (19.0% vs.13.7%; p Z 0.002). No other
demographics were more likely among readmitted patients.
Economic outcomes
Economic outcomes of the administrative database are pre-
sented in Table 1. A secondary diagnosis was associated with
increased costs, longer length of stay, greater mortality, and
increased admission to the intensive care unit (ICU; all
p< 0.001). A significantly higher proportion of patients with
primary diagnoses were receiving Medicare (a U.S. federal
insurance program for adults 65 years; p < 0.001).
Readmission database
UTI-related readmission
There were no differences in the demographics, length of
stay, or costs between those readmitted with and withouteach study cohort. aExcluded for the following reasons: eight
zation (not treated with antibiotics), four with diagnosis before
TI-related admission, and two with no UTI on index admission.
Table 1 Comparison of patient and hospital characteristics by diagnosis sequence (primary vs. secondary)
UTI (n Z 2345) Primary (n Z 493) Secondary (n Z 1852) p
Demographics
Age, y, median (IQR) 78 (64e86) 81 (71e87) 77 (62e86) <0.001
Female 1674 (71.4) 368 (75.0) 1306 (70.5) 0.081
White 1798 (76.7) 374 (75.9) 1423 (76.8) 0.693
Black 207 (8.8) 43 (8.7) 164 (8.9) 0.997
Hispanic/Latino 267 (11.4) 60 (12.2) 207 (11.2) 0.591
Other 173 (3.1) 16 (3.2) 58 (3.1) 0.987
Clinical features
LOS, days, median (IQR) 5.0 (3.0e8.0) 4.0 (3.0e5.0) 5.0 (3.0e8.5) <0.001
ICU admission 306 (13) 7 (1.4) 299 (16) <0.001
30-day all-cause readmission 359 (15.3) 71 (14.4) 288 (15.6) 0.557
Readmitted with primary UTI 32 (8.9) 14 (19.7) 18 (6.3) 0.005
Mortality 92 (3.9) 4 (0.8) 88 (4.8) <0.001
Economic features
Total costs, dollars, median (IQR) 8326 (5388e14,179) 5774 (4227e8219) 9393 (5951e16,211) <0.001
Bed costs, dollars, median, (IQR) 5065 (3055e8744) 3715 (2634e5491) 5666 (3526e9807) <0.001
Payor mix
Medicare (%) 68 74 67 0.002
Medicaid (%) 10 6 11 0.002
Private insurance (%) 8 8 9 0.191
Managed care (%) 12 11 11 0.947
Data are number (%) of patients unless specified otherwise.
ICU Z intensive care unit; IQR Z interquartile range; LOS Z length of stay; UTI Z urinary tract infection.
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tients readmitted with UTI [median (interquartile range,
IQR), 15.0 (7.8e22)] compared with those readmitted
without UTI [median (IQR), 19.0 (12e28); p < 0.001].
Based on coding, 111 patients (5.1%) had UTI at the time
of readmission. However, 86 patients were evaluable, 25
patients were excluded from the readmission analysis
(Fig. 1). A comparison between index and UTI-related
readmission visits is shown in Table 2. Nearly 60% of read-
missions came from a health-care (skilled nursing, long-
term or acute care) facility, approximately two times as
likely as their index admission (33%). With respect to clin-
ical attributes, the rates of primary diagnoses, ICU admis-
sion, and development of bacteremia were similar between
index and readmission visits.
Pathogen distribution
The distribution of causative organisms varied among pa-
tients (Table 2). Gram-negative organisms predominated,
with Escherichia coli being the most commonly isolated
pathogen. However, the occurrence of each pathogen
changed considerably depending on hospital visit. There
were 16.3% of patients (n Z 14) infected with the same
causative pathogen on index and readmission visits. The
occurrence of Gram-positive organisms increased upon
readmission, including a significant increase in the inci-
dence of Enterococcus faecalis (1.2 vs. 9.3%; p Z 0.046).
With respect to Gram-negative organisms, the occurrence
of Enterobacteriaceae infection remained most prominent,
but were reduced by nearly half in the readmitted cases
(p Z 0.006). The proportion of infection with E. coli was
significantly lower for the readmitted cases (p < 0.001).Susceptibility profile
In vitro susceptibility test results of isolated pathogens from
readmitted patients by visit are summarized in Table 3. No
statistically significant differencewas detected between the
two admissions for the incidence of extended-spectrum
beta-lactamases or vancomycin-resistant enterococci.
Among tested isolates, susceptibility profiles were similar
between admissions for ampicillin, ceftriaxone, ciprofloxa-
cin, levofloxacin, trimethoprimesulfamethoxazole, and
vancomycin. By contrast, a higher proportion of readmission
pathogens were nonsusceptible to cefazolin (pZ 0.004) and
cefepime (p Z 0.05). There were increased rates of non-
susceptibility among urinary isolates between index, first,
and second UTI-related readmission (not shown) visits to the
most commonly usedGram-positive (vancomycin) and Gram-
negative (ceftriaxone) antibacterial therapy. We noted a
trend between vancomycin/ceftriaxone nonsusceptibility,
rates of appropriate empiric therapy, and time to appro-
priate therapy, as depicted in Fig. 2.
Initial antibiotic therapy was similar between visits.
Noncarbapenem beta-lactams were primarily used. In both
admissions, ceftriaxone and vancomycin were the most
used agents for Gram-negative and Gram-positive
coverage, respectively. In-house days of antibiotics were
similar between admissions (p Z 0.398). However, median
days of inappropriate antibiotics were prolonged in the
readmission visit (p Z 0.005).
Outcomes
Outcomes for readmitted patients by visit are shown in
Table 3. Readmitted patients were less likely to receive
Table 2 Comparison of index versus readmission visits for patients readmitted with UTI within 30 days
Characteristics Index admission (n Z 86) Readmission (n Z 86) p
Primary diagnosis 25 (29.1) 27 (31.4) 0.850
ICD-9-CM sequence, median (IQR) 3.0 (1.0e4.0) 2.5 (1.0e4.0) 0.976
Transfer from another health-care facility 33 (38.4) 51 (59.3) 0.010
Clinical features
ICU admission 10 (11.6) 14 (16.3) 0.453
Bacteremia 6 (7.0) 4 (4.7) 0.752
Infectious diseases consultation 22 (25.6) 10 (11.9) 0.031
Empiric beta-lactam (noncarbapenem) 67 (77.9) 69 (80.2) 1.000
Discharge to SNF/LTC 51 (58.1) 49 (57.0) 1.000
Epidemiology by admission
Urine culture positive 74 (86.0) 69 (80.2) 0.424
Same pathogena d 14 (16.3) d
Different pathogen d 19 (22.1) d
Multiple bacterial morphologies 18 (20.9) 11 (12.8) 0.211
Gram-positive pathogen 8 (9.3) 14 (16.3) 0.121
Enterococcus faecalis 1 (1.2) 8 (9.3) 0.046
Enterococcus faecium 1 (1.2) 4 (4.7) 0.248
Staphylococcus sp. (except S. aureus) 3 (3.5) 1 (1.2) 0.480
Gram-positive (Gram stain only) 2 (2.3) 1 (1.2) 1.000
Gram-negative pathogen 49 (57.0) 38 (45.3) 0.289
Enterobacteriaceae 43 (50.0) 22 (25.6) 0.006
Escherichia coli 28 (32.5) 10 (11.6) <0.001
Klebsiella pneumoniae 7 (8.1) 4 (4.7) 0.450
Proteus mirabilis 4 (4.7) 1 (1.2) 0.617
Pseudomonas aeruginosa 5 (5.8) 6 (7.0) 0.617
Lactose-fermenting GNR 1 (1.2) 5 (7.2) 0.221
Nonlactose-fermenting GNR 0 4 (5.8) 0.129
Other (1 patient each) 4 (4.7) 8 (9.3) d
a Patients without positive cultures and those with multiple bacterial morphologies were not evaluable for determination of the same
isolated pathogen.
Data are number (%) of patients unless specified otherwise.
GNR Z Gram-negative rod; ICD-9-CM Z International Classification of Diseases 9th Edition Clinical Modification code; ICU Z intensive
care unit; IQR Z interquartile range; LTC Z long-term care; SNF Z skilled nursing facility; UTI Z urinary tract infection.
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a result, time to appropriate therapy was delayed
(p Z 0.045). The length of stay and total hospital costs
were similar between admissions.
The 15 patients (20%) readmitted with UTI on third
admission experienced high rates of inappropriate empiric
therapy and delays in time to appropriate therapy [median
(IQR) 49 hours (5.5e74.0)], despite similar length of stay
(median 5 days, p Z 0.118) and costs (median $9677,
p Z 0.168; data not shown).Discussion
In this study, we evaluated the demography and burden of
care of patients admitted with UTI to our institution, with a
particular emphasis on those readmitted within 30 days. In
general, we found the impact of this infection on the
health-care system to be extensive. The total cost of hos-
pitalization is $8326/patient and driven by length of stay
(median 5 days). Previous reports have focused on com-
munity- or hospital-acquired populations with limited data
on the implications of those presenting to hospital withUTI.1,2,5,6 Our approach complements the available litera-
ture by establishing a benchmark measurement of the
demography and burden of care for patients admitted to
hospital with UTI to track progress in the efforts to prevent
and lower readmission rates over time.
Beyond the initial presentation, herein, we describe the
characteristics and economic implications of this omni-
present condition, as well as a striking alteration in the
epidemiology and resistance profile, between admissions
for readmitted patients. Of late, readmissions have been an
area of heavy scrutiny, and are considered a quality of care
measure and that hospitals are being penalized for
“excessive readmissions” in certain conditions.7 Recent
surveillance data report readmission rates varying from 13%
to 25% for common conditions in the Medicare pop-
ulation.8e10 Although urinary traction infection is not
currently a penalized event by the Centers for Medicare
and Medicaid (U.S. health program families and individuals
with low income and resources) Services, given the high
frequency and resource utilization of this common geriatric
infection, it will likely be a forthcoming focus. We observed
a readmission rate of 16.4% for patients with UTI. A single
ICD-9-CM code was chosen to identify patients, as this is
Table 3 Comparison of index versus readmission nonsusceptibility, initial antibiotics, and outcomes
Index admission (n Z 86) Readmission (n Z 86) p
Nonsusceptibility
ESBL 4 (4.7) 6 (5.8) 0.716
VRE 1 (1.2) 4 (4.7) 0.364
Ampicillin 23/43 (53.5) 18/29 (62.1) 0.632
Cefazolin 11/45 (24.4) 14/22 (63.6) 0.004
Cefepime 4/46 (8.7) 8/29 (27.6) 0.050
Ceftriaxone 5/43 (11.6) 7/22 (31.8) 0.087
Ciprofloxacin 13/46 (28.3) 10/27 (37.0) 0.604
Levofloxacin 13/45 (28.9) 10/36 (27.8) 0.499
Trimethoprimesulfamethoxazole 8/43 (18.6) 8/23 (34.8) 0.246
Vancomycin 1/3 (33.3) 4/5 (80.0) 0.464
Initial antibiotic therapy
Ceftriaxone 46 (53.5) 45 (52.3) 1.000
Vancomycin 15 (17.4) 24 (27.9) 0.095
Cefepime 13 (15.1) 15 (17.4) 0.814
Levofloxacin 8 (9.3) 7 (8.1) 1.000
Ciprofloxacin 6 (7.0) 6 (7.0) 1.000
Piperacillinetazobactam 5 (5.8) 5 (5.8) 1.000
Cefazolin 3 (3.5) 2 (2.3) 1.000
Trimethoprimesulfamethoxazole 1 (1.2) 1 (1.2) 1.000
Ertapenem 1 (1.2) 1 (1.2) 1.000
Outcomes
In-house days of antibiotics, median (IQR) 5.0 (3.0e7.0) 4.0 (3.0e6.0) 0.398
In-house days of inappropriate antibiotics, median (IQR) 0.0 (0.0e0.25) 1.5 (0.0e3.0) 0.005
Discharged on antibiotics 26 (30.2) 20 (25.0) 0.327
Length of hospital stay, days, median (IQR) 5.5 (4.0e8.0) 5.0 (3.0e8.0) 0.515
Total hospital costs, dollars, median (IQR) 9119 (5593e13,582) 8184 (5725e13,446) 0.544
Time to appropriate antibiotics, hours, median (IQR) 4 (1.5e19.0) 17.25 (2.6e50.75) 0.045
Patients who never received appropriate antibiotics 2 (2.3) 7 (8.1) 0.008
Appropriate empiric antibiotics 45/54 (83.3) 28/50 (56.0) 0.009
Data are number (%) of patients unless specified otherwise.
ESBL Z extended-spectrum beta-lactamase; IQR Z interquartile range; VRE Z vancomycin-resistance enterococci.
Figure 2. Association between vancomycin/ceftriaxone
nonsusceptibility and appropriate antibacterial therapy.
Vancomycin/ceftriaxone nonsusceptibility was determined
for patients with positive urine cultures (based on isolated
pathogens and/or Gram stains). Patients with multiple
bacterial morphologies and no growth on urine culture were
not included in the determination of vancomycin/ceftriaxone
nonsusceptibility. UTIZ urinary tract infection.
522 S.H. MacVane et al.most commonly used billing code for UTI at our institution.
However, it is possible that additional patients were read-
mitted with UTI and billed under an alternative code.
Furthermore, the inclusion of patients receiving private
insurance may have lowered our observed rate of read-
mission, as this population has been shown to experience a
lower frequency of readmission, likely a result of overall
better health (fewer comorbid conditions), higher incomes,
and fewer risk factors for recurrent infections when
compared with Medicare beneficiaries.11e13 Despite this,
the high frequency of UTI in the hospital setting translates
into a significant total number of readmissions, regardless
of the exact incidence.
Our comparison of index and readmission visits, for pa-
tients rehospitalized within 30 days, attests to the notion of
antibiotic use leading to the emergence and development
of resistance. While this correlation may seem obvious,
previous investigations have generally relied on surveil-
lance data to demonstrate the relationship.14 In this study,
the changing epidemiology and rise in resistance after
treatment occurred in the same exposed patient popula-
tion. The most alarming difference was the decline in the
incidence of tradition uropathogens. On index admission,
one-half of UTI episodes were due to Enterobacteriaceae
UTI demography and burden of care 523infection, with E. coli being the most common occurrence.
On readmission, rates of infection showed a numerical shift
from Gram-negative to Gram-positive, including a signifi-
cant reduction in the incidence of Enterobacteriaceae
infection (50% vs. 25.6%, p Z 0.006). Because many pa-
tients received appropriate initial therapy and a limited
percentage (1 of 6 patients) were readmitted with the same
isolated pathogen, the main causes of readmission in the
study are likely a combination of reinfection, poorly
managed follow up, failure to correct underlying causes, or
unrelated admissions. Accordingly, the shifting landscape
of uropathogens challenged the ability to provide sufficient
antibiotic coverage on subsequent admissions. Further-
more, susceptibility test results were adversely affected
between visits. There were dramatic increases in the rates
of resistance to conventional urinary antibiotics (Table 3),
including significantly higher rates of nonsusceptibility to
cefepime and cefazolin. Applying the rates of non-
susceptibility to the most commonly used antibiotics for
Gram-positive (vancomycin) and Gram-negative (ceftriax-
one) coverage at our institution substantially diminished
the adequacy of empiric therapy, potentially accounting for
the delay in time to appropriate therapy observed in our
cohort. Although not all readmissions are avoidable, these
observations highlight the importance of appropriate
treatment, correction of modifiable risk factors (i.e.,
indwelling catheter), and follow-up care for nonresponders
as proposed strategies to reduce preventable rehospitali-
zations related to the initial hospital presentation.
Interestingly, although there were notable differences in
the infectious etiology between hospital visits, we saw
comparable length of stay and costs of hospitalization be-
tween admissions for the readmitted patients. However,
subsequent admissions (first and second readmission)
required the use of broader spectrum agents to effectively
treat the more resistant organisms seen in these infections.
In turn, there are potential downstream environmental and
collateral consequences that may not have been captured
in the scope of this study.15e17
As with other studies limitations exist with our current
methodology. First, these data were obtained from a single
hospital. Although data from multiple centers would be of
interest, we used minimal exclusionary criterion yielding a
diverse population that is likely representative of patients
at other hospitals. Second, we evaluated patients based on
the presence of a diagnostic billing code, rather than a
clinical diagnosis, which potentially may have misclassified
or failed to capture the frequency of UTI.18 Third, we
considered readmission to our institution only, and may not
have detected readmitted patients who presented to an
outside institution. Fourth, the study design was retro-
spective in nature and therefore inherently introduces
certain levels of bias.
In conclusion, the burden of disease for patients
admitted to hospital with UTI is high. A majority of patients
with UTI requiring admission to hospital are frequently
those aged 65. A considerable portion of their cost can be
attributed to length of stay. Importantly, subsequent visits
with UTI, where the burden is comparable with that of
index admissions, are associated with changing epidemi-
ology and complexity of managing their infection. This
understanding is of critical importance to health systemsglobally, given the likely impending payment pressures on
hospitals to reduce unnecessary readmissions, as currently
seen in the United States. Further studies with an emphasis
of understanding UTI management processes should be of
heightened interest.
Conflicts of interest
D.P.N., S.H.M., and L.O.T report no conflicts of interest
relevant to this article.
Financial support
This work was supported internally by our department.
Acknowledgments
We thank Gil Fortunado for his assistance with data
retrieval. S.H.M. had full access to all of the data in the
study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
References
1. Foxman B. Epidemiology of urinary tract infections: incidence,
morbidity, and economic costs. Am J Med 2002;113:5Se13S.
2. Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA,
Hanley JM, et al. Urologic diseases in America Project:
analytical methods and principal findings. J Urol 2005;173:
933e7.
3. Gandhi T, Flanders SA, Markovitz E, Saint S, Kaul DR. Impor-
tance of urinary tract infection to antibiotic use among hos-
pitalized patients. Infect Control Hosp Epidemiol 2009;30:
193e5.
4. Meddings J, Saint S, McMahon Jr LF. Hospital-acquired
catheter-associated urinary tract infection: documentation
and coding issues may reduce financial impact of Medicare’s
new payment policy. Infect Control Hosp Epidemiol 2010;31:
627e33.
5. Tambyah PA, Knasinski V, Maki DG. The direct costs of noso-
comial catheter-associated urinary tract infection in the era of
managed care. Infect Control Hosp Epidemiol 2002;23:27e31.
6. Kennedy EH, Greene MT, Saint S. Estimating hospital costs of
catheter-associated urinary tract infection. J Hosp Med 2013;
8:519e22.
7. Public Law 111-148, Patient Protection and Affordable Care Act
2010: Part III, Section 3025. Enacted date March 23, 2010.
Washington, DC: U.S. Government Printing Office.
8. Lindenauer PK, Normand SL, Drye EE, Lin Z, Goodrich K,
Desai MM, et al. Development, validation, and results of a
measure of 30-day readmission following hospitalization for
pneumonia. J Hosp Med 2011;6:142e50.
9. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among
patients in the Medicare fee-for-service program. N Engl J Med
2009;360:1418e28.
10. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for
Medicare beneficiaries by race and site of care. JAMA 2011;
301:675e81.
11. Weiss AJ, Elixhauser A, Steiner C. Readmissions to U.S. hospi-
tals by procedure, 2010: statistical brief #154. In: Healthcare
Cost and Utilization Project (HCUP) statistical briefs. Rock-
ville, MD: Agency for Health Care Policy and Research (US);
2006 Feb.
524 S.H. MacVane et al.12. Davis K, Schoen C, Doty M, Tenney K. Medicare versus private
insurance: rhetoric and reality. Health Aff (Millwood); 2002:
W311e24.
13. Hooton TM. Recurrent urinary tract infection in women. Int J
Antimicrob Agents 2001;17:259e68.
14. Turnidge J, Christiansen K. Antibiotic use and resistanced
proving the obvious. Lancet 2005;365:548e9.
15. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN,
Weinstein RA, Burke JP, et al. Infectious Diseases Society of
America and the Society for Healthcare Epidemiology of
America guidelines for developing an institutional program to
enhance antimicrobial stewardship. Clin Infect Dis 2007;44:
159e77.16. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW,
Scheld WM, et al. The epidemic of antibiotic-resistant in-
fections: a call to action for the medical community from the
Infectious Diseases Society of America. Clin Infect Dis 2008;46:
155e64.
17. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D,
Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from
the Infectious Diseases Society of America. Clin Infect Dis
2009;48:1e12.
18. Tieder JS, Hall M, Auger KA, Hain PD, Jerardi KE, Myers AL,
et al. Accuracy of administrative billing codes to detect uri-
nary tract infection hospitalizations. Pediatrics 2011;128:
323e30.
